GH

Guardant Health Inc

GH, USA

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

https://guardanthealth.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GH
stock
GH

Guardant Health (GH): Reassessing Valuation After a Sharp Share Price Recovery Yahoo Finance

Read more →
GH
stock
GH

Nikko Asset Management Americas Inc. Raises Stake in Guardant Health, Inc. $GH MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$99.6818

Analyst Picks

Strong Buy

15

Buy

6

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-36.08

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

26.16 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-7.26 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-17.26 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 92.67% of the total shares of Guardant Health Inc

1.

Vanguard Group Inc

(9.7574%)

since

2025/06/30

2.

BlackRock Inc

(8.8043%)

since

2025/06/30

3.

Capital Research & Mgmt Co - Division 3

(3.9906%)

since

2025/06/30

4.

Baillie Gifford & Co Limited.

(3.8569%)

since

2025/06/30

5.

Deep Track Capital, LP

(3.408%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.9679%)

since

2025/07/31

7.

Amvescap Plc.

(2.8535%)

since

2025/06/30

8.

Eventide Asset Management, LLC

(2.7737%)

since

2025/06/30

9.

Cadian Capital Management LP

(2.5494%)

since

2025/06/30

10.

Citadel Advisors Llc

(2.3564%)

since

2025/06/30

11.

UBS Asset Mgmt Americas Inc

(2.3527%)

since

2025/06/30

12.

Geode Capital Management, LLC

(2.3421%)

since

2025/06/30

13.

Baillie Gifford US Equity Growth

(2.3189%)

since

2024/12/31

14.

iShares Russell 2000 ETF

(2.3108%)

since

2025/08/31

15.

Vanguard Small Cap Index

(2.2903%)

since

2025/07/31

16.

State Street Corp

(2.2771%)

since

2025/06/30

17.

ARK Investment Management LLC

(2.2641%)

since

2025/06/30

18.

Millennium Management LLC

(2.1826%)

since

2025/06/30

19.

Vanguard US Growth Investor

(2.1031%)

since

2025/06/30

20.

Driehaus Capital Management LLC

(1.9852%)

since

2025/06/30

21.

Two Sigma Advisers, LLC

(1.9099%)

since

2025/06/30

22.

Franklin Resources Inc

(1.8603%)

since

2025/06/30

23.

Eventide Gilead N

(1.8437%)

since

2025/06/30

24.

Fuller & Thaler Asset Management Inc

(1.7624%)

since

2025/06/30

25.

Sumitomo Mitsui Trust Group Inc

(1.6283%)

since

2025/06/30

26.

Amova Asset Management Americas, Inc

(1.6282%)

since

2025/06/30

27.

Capital Group Growth Composite

(1.3673%)

since

2025/06/30

28.

American Funds IS® Growth 1

(1.3673%)

since

2025/06/30

29.

Capital Group Growth Fnd of Amer Comp

(1.3306%)

since

2025/06/30

30.

American Funds Growth Fund of Amer A

(1.3306%)

since

2025/06/30

31.

Vanguard Small Cap Growth Index Inv

(1.2906%)

since

2025/07/31

32.

FullerThaler Behavioral Small-Cap Growth

(1.1781%)

since

2025/06/30

33.

Vanguard Health Care Inv

(1.1289%)

since

2025/06/30

34.

FullerThaler Behavioral Sm-Cp Gr R6

(1.0842%)

since

2025/07/31

35.

Vanguard Institutional Extnd Mkt Idx Tr

(1.068%)

since

2025/07/31

36.

ARK Disruptive Innovation Full Composite

(1.0625%)

since

2025/06/30

37.

Franklin Innovation Composite

(1.0594%)

since

2025/06/30

38.

ARK Genomic Revolution

(1.0578%)

since

2025/06/30

39.

Franklin DynaTech A

(1.0024%)

since

2025/07/31

40.

Fidelity Small Cap Index

(0.9607%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.7646

Latest Release

Date

2025-09-30

EPS Actual

-0.39

EPS Estimate

-0.79

EPS Difference

0.4

Surprise Percent

50.6329%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Fair GARP(3.5)
Growth
Moderate Growth(3.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.